Rushil Desai

TL;DR: It has been proposed that the isolation, ex vivo culture, and characterization of CTCs may provide an opportunity to noninvasively monitor the changing patterns of drug susceptibility in individual patients as their tumors acquire new mutations.

TL;DR: Analysis of circulating tumor cells from prostate cancer patients reveals a mechanism that contributes to treatment failure, and a non-invasive method to spot resistance by sequencing RNA transcripts in single circulating tumor Cells (CTCs) is developed.

TL;DR: The impact of the stroma is demonstrated in shaping tumor architecture by altering inherent patterns of tumor glands in human PDAC by quantifying EMT and PRO subpopulations in 319,626 individual cancer cells that can be classified within the context of distinct tumor gland "units".

TL;DR: Combined treatment with paclitaxel and Notch inhibitors achieves sustained suppression of tumorigenesis in orthotopic circulating tumour cell-derived tumour models and points to distinct yet interconverting phenotypes within patient-derived circulating tumours, contributing to progression of breast cancer and acquisition of drug resistance.

TL;DR: Comparisons of single-cell RNA-Seq profiles of CTCs from breast, prostate and lung cancers suggest that β-globin is selectively deregulated in cancer cells, mediating a cytoprotective effect during blood-borne metastasis.